Prostate Cancer

Relugolix (Orgovyx) is the first oral drug in its class to receive FDA approval for the treatment of adults with advanced prostate cancer.

A clear and reliable biomarker to select patients with prostate cancer for active surveillance or focal therapy has not yet been determined but inferring a course of action from existing biomarkers may be possible.

The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.

Research shows that the PARP inhibitor demonstrated superior PFS and OS for patients with metastatic castration-resistant prostate cancer with BRCA1, BRCA2, or ATM alterations.

An update on the PROSPER trial analyzing enzalutamide plus androgen deprivation therapy found a lower risk of death than placebo for patients with non-metastatic CRPC.

Deep-learning algorithms could be used to alert pathologists to suspicious areas of cancer burden prior to clinical assessment, according to Nitin K. Yerram, MD.

The novel androgen receptor-signaling inhibitor led to negative repeat biopsies after 90 days of treatment among men with very-low risk to favorable intermediate risk prostate cancer on active surveillance.

Enzalutamide improved progression-free survival and increased time to prostate-specific antigen progression, compared with bicalutamide, in patients with nonmetastatic castration-resistant prostate cancer.

The agency approved the first PSMA-targeted PET imaging drug to treat men with prostate cancer.

According to researchers, these immuno-oncologic differences may aid in developing a genomically adaptive approach to treating prostate cancer in this patient population.

This trial is the first randomized trial of men with recurring prostate cancer to show that treatment based on advanced molecular imaging can improve disease-free survival rates.

According to the researchers, the high-quality evidence observed thus far supports the endorsement of this scoring system as a new staging system for prostate cancer.

Researchers suggested that platinum-based treatment may be considered an option in a biomarker-positive population of patients with advanced prostate cancer with DNA repair gene aberrations.

The FDA has approved the FoundationOne Liquid CDx to identify patients with BRCA1, BRCA2, and/or ATM alterations in patients with metastatic castration-resistant prostate cancer who may be appropriate for treatment with olaparib.

In a mock tumor board on prostate cancer on Twitter, health care providers came together to discuss real patient cases and present various treatment options for review.

A study presented at the ASTRO Annual Meeting found that adding the advanced PET radiotracer fluciclovine (Axumin) to conventional imaging for patients with recurrent prostate cancer may improve disease-free survival rates.

The FDA has lifted the clinical hold on the phase 1 study of P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

A series of studies indicated that genetic alterations in the BRCA2, PALB2, and ATM genes are associated with prostate cancer risk in men that have a strong family history of prostate cancer and also increases their risk of an aggressive form of the disease.

“Our findings suggest that distinct genetic alterations in the prostate cancers of African American men, in comparison to white men, may contribute to more aggressive prostate cancer and could lead to a higher mortality rate,” said study senior author Jianfeng Xu, DrPH.

Black race was associated with improved prostate cancer-specific mortality and all-cause mortality among men with nonmetastatic prostate cancer who received radiation therapy in this large equal-access health care system.

A third data cut-off reassessment by the German Institute for Quality and Efficiency in Health Care found enzalutamide provided an added benefit for patients with high-risk non-metastatic castration-resistant prostate cancer.

After adjustments for a number of clinical factors and factors related to access to care, the overall survival disparity among men undergoing radical prostatectomy was significantly decreased, but not eliminated, for Black men.

A study published in the Journal of Clinical Oncology found that rucaparib can successfully treat patients with metastatic castration-resistant prostate cancer who have mutated BRCA/BRCA2 genes.

A study found that delaying radiation therapy while remaining on hormone therapy for patients with unfavorable intermediate-risk or high-risk localized prostate cancer to avoid potential exposure to COVID-19 did not negatively impact overall survival.

Among men with advanced prostate cancer, relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks.